STUDY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLUL

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的主要目的是评估一种新药索拉非尼是否是肝癌患者的有效治疗方法。 这项研究中的受试者接受索拉非尼或安慰剂（一种看起来与索拉非尼相同但不含活性药物的片剂）。 迄今为止，超过8787名癌症患者已经将索拉非尼作为单独治疗或与其他化疗药物一起用于几种不同类型的癌症。在对迄今为止从本研究收集的数据进行审查后，注意到接受索拉非尼的患者和接受安慰剂（看起来像索拉非尼的糖丸）的患者之间的总生存期存在显著差异。与服用安慰剂的患者相比，服用索拉非尼的患者平均寿命更长。因此，研究的交叉阶段已经开始，其中服用索拉非尼的受试者可以选择继续服用索拉非尼。服用安慰剂的受试者可选择开始服用索拉非尼。该研究的交叉期将继续进行，直至研究外的索拉非尼治疗替代供应可用。'

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to assess if a new drug, sorafenib, is an effective treatment for patients with liver cancer. Subjects in this study received either sorafenib or placebo (a tablet that looks identical to sorafenib but contains no active drug). To date, over 8787 cancer patients have taken sorafenib either as a lone treatment or together with other chemotherapy drugs for several different types of cancer. Following a review of the data collected from this study so far, a significant difference was noticed in the overall survival between patients receiving sorafenib and patients receiving placebo (sugar pill that looks like sorafenib). Those patients taking sorafenib lived longer on average compared to patients taking placebo. As a result the crossover phase of the study has begun where subjects taking sorafenib have been offered the option to continue taking sorafenib. Subjects taking placebo have been offered the option to begin taking sorafenib. This crossover phase of the study will continue until an alternative supply of sorafenib treatment outside of the study is made available.'